Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...
RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A novel synthetic bone graft showed noninferiority to ...
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that ...
A new nano-sized drug carrier that finds bone tumors and releases treatment exactly where it's needed is here to improve the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results